Furthermore, human GBM is enormously heterogeneous and possesses multiple non-overlapping immunosuppressive mechanisms,25 so it is not surprising that PDE5 inhibition alone is insufficient to prevent tumor progression for most treated patients. This evidence concerns the gene PDE5A and glioblastoma.